KRAS and non-small cell lung carcinoma: Interestingly, only approximately 40 drugs currently have FDA-approved or cleared companion diagnostics across all targeted drugs (11) with NSCLC as a leading example of a disease type with biomarkers of response such as EGFR, ALK, MET, KRAS, ROS, and RET mutation/rearrangements.